Our Healthy Lives Mission — our environmental, social and governance strategy — strives to nurture healthy people, enrich a healthy planet and maintain healthy practice. Within our three Healthy Lives Mission pillars, we are focused on nine priority topics and have set goals and commitments to hold us accountable and help drive the positive impact we aim to create. Here’s a closer look at Kenvue to see if aligning with Starboard could be a smart move for everyday investors. Kenvue’s td ameritrade chief people officer, chief corporate affairs officer, chief technology and data officer, chief scientific officer and group presidents for different regions around the world are also from J&J.
Mục lục
Company Insights: KVUE
The company had a trading volume of 10,506,181 shares, compared to its average volume of 15,326,525. The firm has a market cap of $46.17 billion, a price-to-earnings ratio of 43.78, a PEG ratio of 2.19 and a beta of 1.36. The business’s 50-day simple moving average is $22.84 and its 200 day simple moving average is $20.86. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Over a century ago, Johnson & Johnson practically invented the consumer healthcare industry with products like Band-Aids and Listerine. With more recent brands like Tylenol and Neutrogena to promote, Starboard thinks the company should spend more on marketing, making some strong arguments.
- Accordingly, the non-GAAP financial measures may not be comparable to such similarly titled non-GAAP financial measures used by other companies.
- It now controls the production and sale of top products like Band-Aid, Tylenol, and Neutrogena, and it will offer a dividend, just as its parent company does.
- Johnson & Johnson’s sheer size makes it a safe stock to buy despite the legal challenges.
- The Company uses certain non-GAAP financial measures to supplement the financial measures prepared in accordance with U.S.
- J&J faces thousands of allegations that its talc baby powder and other talc products caused cancer.
- These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation.
reasons why your skincare routine might not be working
The activist investor recently pushed the stock up by announcing a stake in the consumer goods giant that’s behind popular brands such as Tylenol and Listerine. Annual sales growth through 2025 is projected to be about 3% to 4% globally, according to the filing. Until then, Kenvue will adbe stock forecast, price and news qualify as a “controlled company” under the corporate governance rules of the NYSE, the filing said. That will allow Kenvue to avoid certain listing standards, including a requirement that the company’s board be composed of a majority of independent directors. Although Kenvue is technically a separate company, Johnson & Johnson will still play a big role in its operations; the healthcare company will own a 90% stake in the business. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.
The danger is that even a handful of claims could potentially yield devastating results for forex trading profile of accurateforex Kenvue, as its assets and revenue stream won’t nearly be the size of Johnson & Johnson’s. Johnson & Johnson’s sheer size makes it a safe stock to buy despite the legal challenges. Kenvue, however, doesn’t enjoy that same luxury — its cash and cash equivalents as of the end of 2022 total $1.2 billion.
Please bear with us as we address this and restore your personalized lists. Kenvue’s purpose, Realize the Extraordinary Power of Everyday Care, will guide the company’s actions and long-term aspirations, from strategy to talent philosophy, and more. The following table presents the Company’s Research and development expenses for the periods presented.
We put people first
The year-over-year improvement in both measures primarily reflects productivity gains attributable to our global supply chain efficiency initiatives and benefits from value realization. A number of equities research analysts have recently issued reports on KVUE shares. UBS Group upped their target price on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. Jefferies Financial Group started coverage on Kenvue in a research note on Tuesday, September 24th.
Healthy practice
Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care, and our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes.